PathMaker Neurosystems Appoints Industry Veteran John Fletcher as Chairman of Company’s Board of Directors
Boston, Massachusetts, September 20, 2024 – PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, announced today that it has named R. John Fletcher as Chairman of the Company’s Board of Directors. John Fletcher brings more than 35 years of healthcare and medical device experience to PathMaker. He founded Fletcher Spaght Inc., a strategy consulting and venture capital firm, in 1983 and remains active as the Managing Director Emeritus.
“We are truly excited and honored to have John Fletcher joining PathMaker as Chairman of the Board of Directors,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “As we accelerate our efforts in treating ALS non-invasively with the start of our second ALS clinical trial, John’s extensive experience on the boards of privately-held and publicly-traded medtech companies will be an invaluable addition to our Board.”
“I am very pleased to be joining PathMaker’s Board.” Mr. Fletcher commented. “The Company has pioneered a unique approach to treating ALS non-invasively that could bring about a new standard of care – through improved outcomes, lower cost and a better patient experience. I look forward to helping guide the path of the Company.”
For his work on a number of company boards, he was selected as Director of the Year by the National Association of Corporate Directors. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Prior to founding Fletcher Spaght Inc., John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems is a clinical-stage neuromodulation company developing breakthrough non-invasive systems for the treatment of people with serious neurological disorders such as amyotrophic lateral sclerosis (ALS) and stroke. From its headquarters in Boston, PathMaker is collaborating with world-class institutions to develop and bring to market first-in-class products for treating ALS and other neurological disorders with high unmet medical need. More than 30,000 people in the U.S. suffer from ALS, with an additional 6,000 new ALS diagnoses each year in the U.S.
The MyoRegulator® platform is based on PathMaker’s proprietary technology for motor neuron hyperexcitability suppression. MyoRegulator® has been designated by the US Food and Drug Administration (FDA) as a “FDA Breakthrough Device.” MyoRegulator® and MyoRegulator® ALS are investigational medical devices and are limited by Federal law to investigational use only. For more information, please visit the company website at www.pmneuro.com.
Source: PathMaker Neurosystems Inc.
Media contact: PathMaker PR
(617) 535-7696
partnering@pmneuro.com